PITTSBURGH — Mylan Pharmaceuticals Inc. has launched 50 mg and 200 mg tablets for its geneirc antipsychotic drug clozapine.
The pharmaceutical company, a subsidiary of Mylan Inc., said Monday that those clozapine dosages had U.S. sales of about $13.5 million last year, according to IMS Health data.
Mylan added that the new doses complement its already approved and marketed strengths, which are therapeutically equivalent to Novartis’ Clozaril 25 mg and 100 mg.
Clozapine is used for the treatment of schizophrenia and other psychotic disorders, and it’s typically reserved for patients who have failed to respond to other medications.
